Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $10.7 million.

  • Ironwood Pharmaceuticals' Change in Accured Expenses rose 1539710.14% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $767000.0, marking a year-over-year increase of 10284.04%. This contributed to the annual value of -$20.2 million for FY2024, which is 26323.1% down from last year.
  • Ironwood Pharmaceuticals' Change in Accured Expenses amounted to $10.7 million in Q3 2025, which was up 1539710.14% from -$13.8 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Change in Accured Expenses high stood at $19.5 million for Q3 2022, and its period low was -$13.8 million during Q2 2025.
  • In the last 5 years, Ironwood Pharmaceuticals' Change in Accured Expenses had a median value of $69000.0 in 2024 and averaged $361631.6.
  • As far as peak fluctuations go, Ironwood Pharmaceuticals' Change in Accured Expenses crashed by 175250.66% in 2024, and later surged by 1539710.14% in 2025.
  • Ironwood Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $4.1 million in 2021, then tumbled by 48.6% to $2.1 million in 2022, then tumbled by 700.33% to -$12.5 million in 2023, then surged by 54.16% to -$5.8 million in 2024, then soared by 285.9% to $10.7 million in 2025.
  • Its Change in Accured Expenses was $10.7 million in Q3 2025, compared to -$13.8 million in Q2 2025 and $9.7 million in Q1 2025.